Journal
OBSTETRICS AND GYNECOLOGY
Volume 119, Issue 2, Pages 423-426Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/AOG.0b013e318234d97c
Keywords
-
Categories
Funding
- NCI NIH HHS [P50 CA098258-01, P30 CA016672] Funding Source: Medline
Ask authors/readers for more resources
BACKGROUND: The treatment of endometrial cancer in young women who desire future fertility poses several challenges. Oral progestin and progestin-releasing intrauterine devices (IUDs) have been shown to result in regression of endometrial hyperplasia and grade 1 endometrioid endometrial carcinoma. However, limited data are available on the use of these methods in women with grade 2 disease. CASE: An 18-year-old nulliparous woman was diagnosed with a grade 2 endometrial adenocarcinoma. She desired future fertility and therefore underwent placement of a levonorgestrel-releasing IUD. The patient subsequently underwent endometrial sampling every 3 months and remained disease-free 13 months after initial IUD placement. CONCLUSION: A progestin-releasing IUD may be a valid treatment option for grade 2 endometrial cancer in young women who desire to retain fertility. (Obstet Gynecol 2012;119:423-6) DOI:10.1097/AOG.0b013e318234d97c
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available